Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of Gaboxadol in Primary Insomnia

This study has been completed.
Sponsor:
Information provided by:
H. Lundbeck A/S
ClinicalTrials.gov Identifier:
NCT00209963
First received: September 13, 2005
Last updated: March 29, 2007
Last verified: March 2007

September 13, 2005
March 29, 2007
June 2003
Not Provided
Long-term safety in gaboxadol.
Not Provided
Complete list of historical versions of study NCT00209963 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of Gaboxadol in Primary Insomnia
A Prospective Randomised Double-Blind Parallel-Group Placebo-Controlled Study of Gaboxadol in Primary Insomnia

To evaluate the safety and tolerability of gaboxadol in primary insomnia.

To obtain long-term safety and tolerability data with gaboxadol.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Primary Insomnia
Drug: Gaboxadol
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
600
March 2005
Not Provided

Inclusion Criteria:

  • patients with Primary insomnia
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00209963
99784
No
Not Provided
H. Lundbeck A/S
Not Provided
Study Director: Please contact: Annelies van der Hammen Legters H. Lundbeck A/S
H. Lundbeck A/S
March 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP